[1]
|
Lamas Piñeyro, R. (2006) Obesity in Children and Adolescents Topics in Pediatrics. Valdés, M.S. and Vasallo, G.A., Eds. Medical Sciences, Havana.
|
[2]
|
US Food and Drug Administration (2008) CDER Drug and Biologic Approvals for Calendar Year 2005.
|
[3]
|
Buncke, M.C., Diamant, M., Corner, A., Eliasson, B., Malloy, J.L., Shaginian, R.M., et al. (2009) One-Year Treatment with Exenatide Beta-Cell Function Improves, Compare with Insulin Glargine, Metformin in Type 2 Diabetic-Treat Patients: A Randomized, Controlled Trial. Diabetes Care, 32, 762-768. http://dx.doi.org/10.2337/dc08-1797
|
[4]
|
Tushuizen, M.E., Buncke, C.M., Pouwels, P.J., van Waesberghe, J.H., Diamant, M. and Heine, R.J. (2006) Incretinmimetics as a Novel Option for Hepatic Steatosis Therapeutic. Liver International, 26, 1015-1017. http://dx.doi.org/10.1111/j.1478-3231.2006.01315.x
|
[5]
|
Heine, R.J., Van Gaal, L.F., Johns, D., Mihm, M.J., Wideload, M.H., Brodows, R.G., et al. (2005) Exenatide versus Insulin Glargine in Suboptimally Controlled Type with Patients 2 Diabetes: A Randomized Trial. Annals of Internal Medicine, 143, 559-569. http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00006
|